ArticleFrontiers in medicine2026
Hyperviscosity encephalopathy in suspected polycythemia vera at high altitude: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polycythemia vera (PV) is a JAK2-associated clonal myeloproliferative neoplasm characterized by erythroid hyperplasia. To the best of our knowledge, this is the first reported case of acute hyper-viscosity encephalopathy as the initial manifestation of suspected PV in a resident of extreme high altitude-a diagnosis frequently mistaken for altitude-induced secondary polycythemia in this population. Case report: A 37-year-old Tibetan man, lifelong resident at 4,100 m, presented with acute encephalopathy characterized by altered consciousness, gait ataxia, and headache. Neurological examination confirmed higher cortical dysfunction. Laboratory studies showed marked erythrocytosis (hemoglobin 229 g/L, hematocrit 77.4%) with paradoxically suppressed serum erythropoietin (EPO, 1.2 mIU/mL). Brain magnetic resonance imaging (MRI) with diffusion-weighted imaging (DWI) revealed acute bilateral frontoparietal and centrum semiovale diffusion-restricted lesions. Neurological symptoms resolved rapidly after osmotic therapy for intracranial hypertension. These findings were consistent with suspected PV based on WHO diagnostic criteria. Conclusion: This case suggests that acute infection may trigger life-threatening hyper-viscosity syndrome in suspected PV at extreme altitudes. EPO assessment and JAK2 mutational analysis are recommended to be included in the diagnostic algorithm to distinguish malignant PV clones from compensatory polycythemia and to prevent catastrophic neurological outcomes in high-altitude residents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.